

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

28 Jun 2026

### The assessment of the effect of L-carnitine supplementation versus placebo on serum total antioxidant and oxidant capacities, lipid profile in patients with pemphigus vulgaris

#### Protocol summary

##### Summary

This study will be done as a double blind placebo controlled clinical trial on 52 patients with 30 to 65 years old affected by pemphigus vulgaris. The patients presenting to RAZI hospital who affected to the illness at least one year and using Prednisolone will be under study in order to determine the influences of L-carnitine supplementation to the total antioxidant and oxidative capacities, serum lipid profiles, psychological status, fatigue and quality of life. Patients will be divided in two groups according to permuted block randomization by using random code receive 1000 mg of L-carnitine or placebo tablets twice a day. The duration of this intervention is 8 weeks; at the beginning and end of the study, 10 cc blood will be taken from patients for measuring the serum concentration of fasting blood glucose, triglycerides, total cholesterol, HDL, LDL, VLDL, TAC, TOC, F2isoprostane and L-carnitine. The dietary data of the patients also will be collected by a 24-h dietary recall for three days (one holiday day and two usual days) at the beginning and end of the study. Also SF-36, GHQ-12, FSS and DLQI questionnaire will be taken at the beginning and end of the study.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT2015062322769N4**  
Registration date: **2015-08-13, 1394/05/22**  
Registration timing: **prospective**

Last update:

Update count: **0**

##### Registration date

2015-08-13, 1394/05/22

#### Registrant information

##### Name

Mohammad Hassan Javanbakht

##### Name of organization / entity

Tehran University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 8891 4462

##### Email address

mhjavan@sina.tums.ac.ir

#### Recruitment status

##### Recruitment complete

#### Funding source

Tehran University of medical sciences; school of nutritional sciences and dietetics

#### Expected recruitment start date

2015-08-23, 1394/06/01

#### Expected recruitment end date

2016-03-09, 1394/12/19

#### Actual recruitment start date

empty

#### Actual recruitment end date

empty

#### Trial completion date

empty

#### Scientific title

The assessment of the effect of L-carnitine supplementation versus placebo on serum total antioxidant and oxidant capacities, lipid profile in patients with pemphigus vulgaris

#### Public title

The effect of L-carnitine in the treatment of complications of patients with pemphigus vulgaris

#### Purpose

Prevention

## Inclusion/Exclusion criteria

**INCLUSION CRITERIA:** Willingness to cooperate; Affected by pemphigus vulgaris; Minimum one year of pemphigus vulgaris illness; Using Corticosteroid alone or with one of the Methotrexate, Azathioprine and Cellcept drugs; Age between 30 and 65 years old; BMI<35; Lack of Cardiovascular disease, renal, hepatic and inflammatory intestinal diseases; No alcohol consumption; Do not use of any antioxidant supplementation during the last 3 months; No consumption of Cisplatin, Theophylline and Valproate during the past month; Non-smoking and tobacco use (People who have smoked less than five cigarettes daily in previous 6 months); Lack of pregnancy and lactation **EXCLUSION CRITERIA:** Changing the type of used drug; Find allergy symptoms at any time of the study

## Age

From **30 years** old to **65 years** old

## Gender

Both

## Phase

1

## Groups that have been masked

*No information*

## Sample size

Target sample size: **52**

## Randomization (investigator's opinion)

Randomized

## Randomization description

## Blinding (investigator's opinion)

Double blinded

## Blinding description

## Placebo

Used

## Assignment

Parallel

## Other design features

For double blinding the study, all boxes of l-carnitine and placebo tablets will be divided in two groups of 1 and 2 by someone other than researcher. The researcher, physician and the patient will be unaware of this group division. This group division will be done based on a random numbers table.

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Tehran University of Medical Sciences

##### Street address

Sixth Floor, Central department of University, Ghods St., Keshavarz Blvd.

##### City

tehran

##### Postal code

## Approval date

2015-06-14, 1394/03/24

## Ethics committee reference number

IR.TUMS.REC.1394.28

## Health conditions studied

### 1

#### Description of health condition studied

pemphigus vulgaris

#### ICD-10 code

L10.0

#### ICD-10 code description

Pemphigus vulgaris

## Primary outcomes

### 1

#### Description

L-carnitine

#### Timepoint

Before and 8 weeks after intervention

#### Method of measurement

Through the serum by ELISA kit

### 2

#### Description

Osteopentin

#### Timepoint

Before and 8 weeks after intervention

#### Method of measurement

Through the serum by ELISA kit

### 3

#### Description

Total oxidant capacity

#### Timepoint

Before and 8 weeks after intervention

#### Method of measurement

Through the serum by ELISA kit

### 4

#### Description

F2isoprostane

#### Timepoint

Before and 8 weeks after intervention

#### Method of measurement

Through the serum by ELISA kit

### 5

#### Description

Total cholesterol

#### Timepoint

Before and 8 weeks after intervention

#### Method of measurement

Through the serum by colorimetric

## 6

### **Description**

Triglycerides

### **Timepoint**

Before and 8 weeks after intervention

### **Method of measurement**

Through the serum by colorimetric

## 7

### **Description**

Low-density lipoprotein

### **Timepoint**

Before and 8 weeks after intervention

### **Method of measurement**

Through the serum by colorimetric

## 8

### **Description**

High-density lipoprotein

### **Timepoint**

Before and 8 weeks after intervention

### **Method of measurement**

Through the serum by colorimetric

## 9

### **Description**

Fasting Blood sugar

### **Timepoint**

Before and 8 weeks after intervention

### **Method of measurement**

Through the serum by colorimetric

## 10

### **Description**

Added at 2017-08-08:bone morphogenic protein 4

### **Timepoint**

Added at 2017-08-08: Before and 8 weeks after intervention

### **Method of measurement**

Added at 2017-08-08: Through the serum by ELISA kit

## 11

### **Description**

Added at 2017-08-08: cystatin c

### **Timepoint**

Added at 2017-08-08: Before and 8 weeks after intervention

### **Method of measurement**

Added at 2017-08-08: Through the serum by ELISA kit

## 12

### **Description**

Added at 2017-10-05: HOMA-IR

### **Timepoint**

Added at 2017-10-05: Before and 8 weeks after intervention

### **Method of measurement**

Added at 2017-10-05: Serum concentration using ELISA kit

## 13

### **Description**

Added at 2017-10-05: SFRP5

### **Timepoint**

Added at 2017-10-05: Before and 8 weeks after intervention

### **Method of measurement**

Added at 2017-10-05: Serum concentration using ELISA kit

## 14

### **Description**

Added at 2017-10-05: Visfatin

### **Timepoint**

Added at 2017-10-05: Before and 8 weeks after intervention

### **Method of measurement**

Added at 2017-10-05: Serum concentration using ELISA kit

## 15

### **Description**

Added at 2017-10-05: Omentin

### **Timepoint**

Added at 2017-10-05: Before and 8 weeks after intervention

### **Method of measurement**

Added at 2017-10-05: Serum concentration using ELISA kit

## **Secondary outcomes**

### 1

#### **Description**

Quality of life

#### **Timepoint**

at the beginning and at the end of the study

#### **Method of measurement**

SF-36, GHQ-12, FSS and DLQI questionares

### 2

#### **Description**

Added at 2017-10-05: QUICKI

#### **Timepoint**

Added at 2017-10-05: Before and 8 weeks after intervention

#### **Method of measurement**

Added at 2017-10-05: Serum concentration using ELISA kit

### 3

#### **Description**

Added at 2017-10-05: Insulin

#### **Timepoint**

Added at 2017-10-05: Before and 8 weeks after intervention

#### Method of measurement

Added at 2017-10-05: Serum concentration using ELISA kit

## Intervention groups

### 1

#### Description

The use of pill type L-carnitine supplement produced by KAREN chemistry company in 1000 mg dose twice a day (morning and evening) for 8 weeks

#### Category

Treatment - Drugs

### 2

#### Description

The use of pill type placebo produced by KAREN chemistry company in 1000 mg dose twice a day (morning and evening) for 8 weeks

#### Category

Placebo

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Hospital Razi skin

##### Full name of responsible person

Mohamad Hasan Javanbakht/PHD Nutrition/Assistant Professor and Faculty member of School of Nutrition

##### Street address

HAFEZ St., VAHDAT ESLAMI Ave., VAHDAT ESLAMI Sq.

##### City

Tehran

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Vice chancellor for research, Tehran University of Medical Sciences

##### Full name of responsible person

Masud Yunesian

##### Street address

Sixth Floor, Central department of University, Ghods St., Keshavarz Blvd.

##### City

Tehran

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Vice chancellor for research, Tehran University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

empty

#### Domestic or foreign origin

empty

#### Category of foreign source of funding

empty

#### Country of origin

#### Type of organization providing the funding

empty

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences

##### Full name of responsible person

Mohammad Hasan Javanbakht

##### Position

PHD Nutrition/Assistant Professor and Faculty member of School of Nutritional Sciences and Dietetics

##### Other areas of specialty/work

##### Street address

No. 44, Hojatdost Alley, Naderi St., Keshavarz Blvd.

##### City

Tehran

##### Postal code

##### Phone

+98 21 8898 5908

##### Fax

##### Email

mhjavan2001@yahoo.com

##### Web page address

## Person responsible for scientific inquiries

#### Contact

##### Name of organization / entity

School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences

##### Full name of responsible person

Mohammad Hasan Javanbakht

##### Position

PHD Nutrition

##### Other areas of specialty/work

##### Street address

No. 44, Hojatdost Alley, Naderi St., Keshavarz Blvd.

##### City

Tehran

##### Postal code

##### Phone

+98 21 8898 5908

##### Fax

##### Email

mhjavan2001@yahoo.com

##### Web page address

## Person responsible for updating data

### Contact

**Name of organization / entity**

School of Nutritional Sciences and Dietetics, Tehran  
University of Medical Sciences

**Full name of responsible person**

Mohammad Hasan Javanbakht

**Position**

PHD Nutrition/Assistant Professor and Faculty  
member of School of Nutritional Sciences and  
Dietetics

**Other areas of specialty/work****Street address**

No. 44, Hojatdost Alley, Naderi St., Keshavarz Blvd.

**City**

Tehran

**Postal code****Phone**

+98 21 8898 5908

**Fax****Email**

mhjavan2001@yahoo.com

**Web page address**

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*